Skip to main content
. 2013 Jan 24;8(1):e52950. doi: 10.1371/journal.pone.0052950

Figure 5. Relationship between nevirapine trough concentration and underlying liver diseases.

Figure 5

The differences for nevirapine trough concentration between lead-in and steady-state periods was observed in patients with HBV infection (A). The nevirapine trough concentration at week 4 was significantly lower than the values at week 24, 36 and 48 (P<0.05) in patients with HCV infection (B). The nevirapine trough concentration at week 48 in patients with HCV infection was significant higher than those without HCV coinfection (P = 0.004).